Literature DB >> 483790

Fiberoptic bronchoscopy in diagnosis of opportunistic lung infections: assessment of Sputa, Washings, Brushings and biopsy specimens.

S K Chopra, Z Mohsenifar.   

Abstract

Fiberoptic bronchoscopy (washings, brushings and biopsies) was done in 25 cases of proven opportunistic pulmonary infections in compromised hosts. Diagnostic yields of bronchoscopic procedures and expectorated sputum were compared. Sputum examination gave the lowest yield (14 percent). Bronchial washings and brushings were diagnostic in 30 percent and 38 percent of patients, respectively. On transbronchial biopsy of the lung (TBB) pathogens were identified in 75 percent of patients with Pneumocystis carinii infection and 67 percent of patients with other opportunistic infections. The overall TBB yield of 73 percent was superior (P<0.05) to that of either washings or brushings. The yield from combining washings and brushings was greater than from either procedure alone, but combination with TBB did not result in any significant improvement. TBB is recommended as a useful diagnostic procedure in patients with suspected opportunistic pulmonary infections. Morbidity was minimal with this procedure, and the need for thoracotomy was reduced when it was used.

Entities:  

Mesh:

Year:  1979        PMID: 483790      PMCID: PMC1271617     

Source DB:  PubMed          Journal:  West J Med        ISSN: 0093-0415


  16 in total

1.  A mycologic study of 71 autopsies.

Authors:  L D HALEY; A McCABE
Journal:  Am J Clin Pathol       Date:  1950-01       Impact factor: 2.493

2.  Pulmonary infiltrates and fever in patients with hematologic malignancy: assessment of transbronchial biopsy.

Authors:  J E Pennington; N T Feldman
Journal:  Am J Med       Date:  1977-04       Impact factor: 4.965

3.  Fiberoptic bronchoscopy in the diagnosis of lung cancer comparison of pre-and post-bronchoscopy sputa, washings, bruchings and biopsies.

Authors:  S K Chopra; M G Genovesi; D H Simmons; B Gothe
Journal:  Acta Cytol       Date:  1977 Jul-Aug       Impact factor: 2.319

4.  Lung biopsy: transbronchoscopic, percutaneous, open.

Authors:  H A Andersen; W E Miller; P E Bernatz
Journal:  Surg Clin North Am       Date:  1973-08       Impact factor: 2.741

5.  Transbronchial lung biopsy using fiberoptic bronchoscope.

Authors:  S K Chopra; F Ben-Isaac
Journal:  South Med J       Date:  1977-03       Impact factor: 0.954

Review 6.  Pulmonary infection in the compromised host: part I.

Authors:  D M Williams; J A Krick; J S Remington
Journal:  Am Rev Respir Dis       Date:  1976-08

7.  Diagnosis of Pneumocystis carinii pneumonitis by means of endobronchial brush biopsy.

Authors:  L H Repsher; G Schröter; W S Hammond
Journal:  N Engl J Med       Date:  1972-08-17       Impact factor: 91.245

8.  Transbronchial lung biopsy in the compromised host.

Authors:  N T Feldman; J E Penningtonp; M G Ehrie
Journal:  JAMA       Date:  1977-09-26       Impact factor: 56.272

9.  Transtracheal selective bronchial brushing for pulmonary infiltrates in patients with cancer.

Authors:  J Aisner; L K Kvols; E A Sickles; S C Schimpff; P H Wiernik
Journal:  Chest       Date:  1976-03       Impact factor: 9.410

10.  Pneumocystis carinii pneumonia. Diagnosis by examination of pulmonary secretions.

Authors:  W K Lau; L S Young; J S Remington
Journal:  JAMA       Date:  1976-11-22       Impact factor: 56.272

View more
  3 in total

1.  Role of bronchoalveolar lavage in immunocompromised patients with pneumonia treated with a broad spectrum antibiotic and antifungal regimen.

Authors:  I A Hohenadel; M Kiworr; R Genitsariotis; D Zeidler; J Lorenz
Journal:  Thorax       Date:  2001-02       Impact factor: 9.139

2.  The diagnostic role of fiberoptic bronchoscopy in AIDS patients with suspected Pneumocystis carinii pneumonia.

Authors:  U Pedersen; I M Hansen; J Böttzauw
Journal:  Arch Otorhinolaryngol       Date:  1989

3.  Usefulness of transbronchial biopsy in immunosuppressed patients with pulmonary infiltrates.

Authors:  S Puksa; M A Hutcheon; R H Hyland
Journal:  Thorax       Date:  1983-02       Impact factor: 9.139

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.